CJC-1295 and ipamorelin: what the blend is

What this comes down to

• The two act at different points on the growth hormone system, which is the reason given for blending them. Our stated PubMed search found no indexed randomized-trial reports on the combination.
• Two CJC-1295 trials reported in one 2006 paper raised growth hormone and IGF-I in healthy adults and reported no serious adverse reactions. It did not measure muscle, fat, sleep or recovery.
• Ipamorelin's phase 2 trial, in 114 bowel-surgery patients, found no significant difference from placebo.
• The FDA puts ipamorelin acetate on its list of compounding substances that may present significant safety risks, and says it has identified serious adverse events with CJC-1295, including increased heart rate.

Why are CJC-1295 and ipamorelin sold together?

Because they push on the same system from two sides. CJC-1295 is a long-acting version of growth-hormone-releasing hormone, the signal the brain uses to tell the pituitary to release growth hormone^[1]. Ipamorelin works on a different receptor, the one the hunger hormone ghrelin uses, which also triggers growth hormone release^[2]. Sellers combine them on the idea that two signals add up. Our stated search did not find randomized-trial reports testing that idea.

Trials of the two together. A PubMed search finds 0 results; the same search for cagrilintide with semaglutide finds 13.

What did the trials of each one find?

One 2006 publication reports two randomized, placebo-controlled CJC-1295 trials in healthy adults aged 21 to 61, lasting 28 and 49 days. A single injection raised growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, and no serious adverse reactions were reported^[1]. Those are hormone levels, not outcomes; nothing in the trial measured muscle, fat or how anyone felt. CJC-1295's evidence goes through it in full.

Ipamorelin was taken into a phase 2 trial by a drug company. 117 adults having bowel surgery were enrolled, and 114 were analyzed; they got ipamorelin or placebo through an IV twice a day for up to a week. The median time to a first tolerated meal was 25.3 hours on ipamorelin against 32.6 hours on placebo, and the authors found no significant difference on that or any secondary measure^[2]. It is one of two randomized trials of ipamorelin in people^[3]; ipamorelin's evidence covers both.

Is CJC-1295 or ipamorelin FDA-approved?

No. No approved product in the FDA's database lists either one as an active ingredient^[4]. Ipamorelin acetate sits on the FDA's list of compounding substances that may present significant safety risks, added in September 2023 for the outsourcing-facility route, and CJC-1295 appears on the same page among nominations that were later withdrawn, with the agency's safety text still published^[5]. Neither was part of the July 2026 advisory panel vote on peptides; are peptides legal? explains that vote, and every peptide's FDA status puts both in one table with the rest of the menu.

Approved products containing either peptide. A Drugs@FDA search finds 0 results; the same search for tesamorelin through the identical field finds 1.

What side effects have been reported?

The trials report little, because they were small and short. The two CJC-1295 trials reported in 2006 found no serious adverse reactions^[1]. In ipamorelin's trial, side effects of any kind were common in both groups, 87.5% on ipamorelin and 94.8% on placebo, as expected after major surgery^[2]. The FDA's own entries say more:

“FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”

^[5]

For ipamorelin, the agency cites a risk of immune reactions from impurities in compounded versions, and says a published study found serious adverse events, including death, when ipamorelin was given through an IV for gut motility^[5]. The FDA entry links directly to the Beck 2014 study discussed above and identifies serious adverse events, including death. The abstract alone does not provide a death count or establish whether a death was caused by the drug. These findings do not establish the safety of injecting the blend under the skin at home.

Who sells CJC-1295 and ipamorelin through telehealth?

Live Vital prices the blend at $116 a month on a ten-week protocol. Blis MD and ElitePhysiqMD also name it on their menus. A telehealth prescription means a clinician reviews your health history and a licensed compounding pharmacy fills it. Websites selling the same peptides as "research use only" skip both, and the label means the product is not meant for people.

• Ask which pharmacy compounds it and check its license. Checking a compounding pharmacy shows how.
• Ask what testing each lot gets. Purity and testing for injectable peptides explains what a certificate of analysis covers.
• Compare with the alternatives on the same system: sermorelin online and tesamorelin, the one with an FDA approval.

Questions people actually ask